Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kadara H et al. – Stage I NSCLC patients with positive UBE2C expression exhibited significantly poorer overall and progression–free survival than patients with negative expression. The studies with this in vitro model have lead to the identification of a robust six–gene signature, which may be valuable for predicting the survival of lung adenocarcinoma patients. Moreover, one of those genes, UBE2C, seems to be a powerful biomarker for NSCLC survival prediction.

Related Articles

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers
European Journal of Cardio-Thoracic Surgery, 12/09/09    Relevance Score: 69%%

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
Oncogene, 11/30/09    Relevance Score: 66%%

Down-Regulation of FXYD3 Expression in Human Lung Cancers. Its Mechanism and Potential Role in Carcinogenesis
American Journal of Pathology, 11/09/09    Relevance Score: 66%%

Intervals Between Lung Cancer Diagnosis And Treatment Displays A Health Care Disparity
ScienceDaily, 11/02/09    Relevance Score: 66%%

Bronchiolar Progenitor Cells
Proceedings of the American Thoracic Society, 12/04/09    Relevance Score: 65%%

Today in Carcinogenesis...keeping you current

Regulating the leukaemia stem cell
Best Practice & Research: Clinical Haematology , 12/09/09

Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways
Endocrine-Related Cancer, 12/08/09

Activation of the hedgehog-signaling pathway in human cancer and the clinical implications
Oncogene, 11/30/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address